Matrix Asset Advisors Inc. NY grew its stake in Merck & Company, Inc. (NYSE:MRK) by 3.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 145,840 shares of the company’s stock after acquiring an additional 5,275 shares during the period. Merck & Company, Inc. accounts for approximately 1.6% of Matrix Asset Advisors Inc. NY’s holdings, making the stock its 27th largest position. Matrix Asset Advisors Inc. NY’s holdings in Merck & Company, Inc. were worth $9,347,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in MRK. Perennial Advisors LLC lifted its stake in Merck & Company, Inc. by 10.7% in the 2nd quarter. Perennial Advisors LLC now owns 1,626 shares of the company’s stock valued at $104,000 after purchasing an additional 157 shares during the last quarter. Stelac Advisory Services LLC acquired a new stake in Merck & Company, Inc. in the 2nd quarter valued at about $104,000. Cascade Investment Advisors Inc. lifted its stake in Merck & Company, Inc. by 15.5% in the 2nd quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock valued at $111,000 after purchasing an additional 232 shares during the last quarter. Solaris Asset Management LLC lifted its stake in Merck & Company, Inc. by 6.3% in the 2nd quarter. Solaris Asset Management LLC now owns 1,940 shares of the company’s stock valued at $124,000 after purchasing an additional 115 shares during the last quarter. Finally, Harbour Capital Advisors LLC acquired a new stake in Merck & Company, Inc. in the 1st quarter valued at about $127,000. Institutional investors own 73.85% of the company’s stock.

Several brokerages have issued reports on MRK. J P Morgan Chase & Co set a $70.00 price objective on shares of Merck & Company, Inc. and gave the stock a “buy” rating in a research report on Sunday, October 29th. Berenberg Bank restated a “hold” rating on shares of Merck & Company, Inc. in a research report on Wednesday, November 1st. Bank of America began coverage on shares of Merck & Company, Inc. in a research report on Tuesday. They set a “buy” rating and a $64.00 price objective for the company. Sanford C. Bernstein restated a “buy” rating and set a $64.00 price objective on shares of Merck & Company, Inc. in a research report on Wednesday, November 15th. Finally, BMO Capital Markets set a $70.00 price objective on shares of Merck & Company, Inc. and gave the stock a “buy” rating in a research report on Wednesday, October 18th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have given a buy rating to the stock. Merck & Company, Inc. has a consensus rating of “Hold” and a consensus price target of $66.29.

In other Merck & Company, Inc. news, Director Thomas H. Glocer sold 5,000 shares of the business’s stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $56.20, for a total transaction of $281,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.25% of the company’s stock.

Shares of Merck & Company, Inc. (NYSE MRK) traded up $0.60 during trading hours on Friday, reaching $55.87. 12,092,384 shares of the company were exchanged, compared to its average volume of 9,625,131. The company has a market capitalization of $152,380.00, a PE ratio of 14.12, a price-to-earnings-growth ratio of 2.54 and a beta of 0.78. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.43 and a quick ratio of 1.16. Merck & Company, Inc. has a fifty-two week low of $53.63 and a fifty-two week high of $66.80.

Merck & Company, Inc. (NYSE:MRK) last posted its earnings results on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, topping analysts’ consensus estimates of $1.03 by $0.08. The firm had revenue of $10.33 billion for the quarter, compared to analysts’ expectations of $10.54 billion. Merck & Company, Inc. had a net margin of 11.60% and a return on equity of 27.08%. The company’s revenue was down 2.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.07 earnings per share. sell-side analysts predict that Merck & Company, Inc. will post 3.95 EPS for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Monday, January 8th. Shareholders of record on Friday, December 15th will be paid a dividend of $0.48 per share. This represents a $1.92 dividend on an annualized basis and a dividend yield of 3.44%. The ex-dividend date of this dividend is Thursday, December 14th. This is a boost from Merck & Company, Inc.’s previous quarterly dividend of $0.47. Merck & Company, Inc.’s payout ratio is presently 182.52%.

COPYRIGHT VIOLATION WARNING: “Matrix Asset Advisors Inc. NY Has $9.35 Million Stake in Merck & Company, Inc. (MRK)” was published by Daily Political and is the property of of Daily Political. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/12/01/matrix-asset-advisors-inc-ny-has-9-35-million-stake-in-merck-company-inc-mrk.html.

Merck & Company, Inc. Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Company, Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.